1. Homepagina
  2. Aandelen
  3. Japan
  4. Japan Exchange
  5. Eisai Co., Ltd.
  6. Nieuws
  7. Persberichten
    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Rapport
Vertraagde tijd Japan Exchange  -  08:00 10-08-2022
6095.00 JPY   -0.07%
08/08Winst en inkomsten van Eisai in fiscaal kwartaal 1 dalen door hogere verkoop- en administratiekosten
MT
05/08Eisai presenteert nieuwe gegevens voor Lecanemab (Ban2401) op de internationale conferentie van de Alzheimer's Association
CI
07/07Japan Index herstelt zich; V Cube aandelen stijgen 5%
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciënConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiële publicatiesSectornieuws
Communiqués de presse de la société EISAI CO., LTD.
05/08Eisai - baseball legend bernie williams teams up with eisai and advocacy partners to la..
AQ
05/08EISAI : CONSOLIDATED FINANCIAL REPORT for the Three-Month Period Ended June 30,2022
PU
05/08EISAI : FY 2022 (Ending March 31, 2023) First Quarter Financial Results Reference Data
PU
04/08Merck and eisai provide update on phase 3 leap-002 trial evaluating keytruda (pembroliz..
AQ
04/08Eisai Presents New Findings on Lecanemab's Investigational Subcutaneous Formulation and..
AQ
04/08Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial
AQ
03/08EISAI : and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-002 Trial Ev..
PU
26/07Latest data on lecanemab to be presented at Alzheimer's Association International Confe..
AQ
26/07Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series
AQ
26/07Eisai to Present at The Alzheimer's Association International Conference (AAIC) 2022
AQ
26/07EISAI : To present the latest lecanemab data, including aria-e and subcutaneous formulatio..
PU
12/07Interim Report for the period April - June 2022
AQ
06/07Eisai Co., Ltd. - THE U.S. FDA ACCEPTS AND GRANTS PRIORITY REVIEW FOR EISAI'S BIOLOGICS..
AQ
06/07U.S. FDA Accepts and Grants Priority Review for Eisai's Biologics License Application o..
AQ
06/07The FDA accepts BLA and grants priority review for lecanemab for treatment of early Alz..
AQ
24/06Eisai Signs the Public-Private Partnership "Kigali Declaration" for Eliminating Neglect..
AQ
22/06PRESSWIRE GLOBAL NEWS DISTRIBUTION : ProMIS Neurosciences Announces Filing of Form 10 Regi..
AQ
22/06Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed ..
AQ
08/06EISAI : Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the..
PU
06/06Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 202..
AQ
06/06EISAI PRESENTS NEW FINDINGS FOR ANTI : #5513)Poster Presentation Features Analyses Based o..
PU
03/06Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting
AQ
30/05EISAI : Announcement of a Summary Share Exchange (kan'i kabushiki kokan) to Make Sunplanet..
PU
27/05Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
AQ
27/05EISAI : MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formula..
AQ
20/05EISAI : “MOVICOL® HD” LaunchedA New Dosage Form Added to Polyethylene Glycol C..
PU
10/05Eisai Initiates Preparation for New Drug Application, Based on the Results of an Invest..
AQ
10/05Eisai completes rolling submission to the FDA of lecanemab for early Alzheimer's diseas..
AQ
03/05EISAI : Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the..
PU
28/04Interim Report for the period January - March 2022
AQ
27/04Modeling published in Neurology and Therapy suggests that lecanemab could delay progres..
AQ
08/04Biogen's Statement on the Final National Coverage Determination for Amyloid-Beta Target..
AQ
08/04Eisai statement on the centers for medicare and medicaid services
AQ
08/04EISAI : Statement on the centers for medicare and medicaid services' national coverage det..
PU
01/04EISAI : Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengt..
PU
31/03Meagan good shares her scare with uterine cancer to encourage people to spot the early ..
AQ
28/03EISAI : Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibito..
AQ
28/03EISAI : Announcement about an approval for additional indication of Jyseleca®, JAK inhibit..
PU
23/03Eisai Co., Ltd - LATEST FINDINGS ON LECANEMAB - CLINICAL EFFICACY, ARIA RATES, BIOMARKE..
AQ
22/03Latest Findings on Lecanemab - Clinical Efficacy, Aria Rates, Biomarkers Relationship t..
AQ
22/03SYSMEX PRESENTS ACADEMIC REPORT IN E : (ad/pdtm 2022)
PU
22/03EISAI : Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
AQ
17/03Biogen Announces Peer-Reviewed Publication of ADUHELM Phase 3 EMERGE and ENGAGE Data in..
AQ
15/03Eisai - ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER'S DISEASE TREATMENT COLLABORATI..
AQ
15/03EISAI : Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration ..
AQ
15/03Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
AQ
15/03EISAI : ECONOMIC ARRANGEMENTS OF AMENDMENT TO ALZHEIMER‘S DISEASE TREATMENT COLLABOR..
PU
11/03Latest lecanemab data to be presented at the AD/PD™ congress
AQ
11/03Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical..
AQ
11/03EISAI : TO PRESENT NEW LECANEMAB DATA EXPLORING DISTINCT MECHANISM OF ACTION AND CLINICAL ..
PU
09/03EISAI : Certified as the 2022 health and productivity management outstanding organization ..
PU
07/03Eisai initiates submission of application data under the prior assessment consultation ..
AQ
07/03LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients w..
AQ
07/03EISAI : Lenvima®(lenvatinib)in combination with keytruda®(pembrolizum..
PU
04/03Eisai initiates submission of application data of lecanemab under the prior assessment ..
AQ
28/02Eisai and Merck & Co., Inc. - LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approv..
AQ
25/02EISAI : LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically..
AQ
25/02EISAI : LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Approved in Japan for Radical..
PU
10/02Eisai submits formal comments to the centers for medicare and medicaid services' propos..
AQ
10/02EISAI : Submits formal comments to the centers for medicare and medicaid services' propose..
PU
03/02EISAI : Reference Data
PU
03/02Interim Report for the period October - December 2021
AQ
03/02EISAI : CONSOLIDATED FINANCIAL REPORT for the Nine-Month Period Ended December 31, 2021
PU
03/02EISAI : FY 2021 (Ended March 31, 2022) Third Quarter Financial Results Reference Data
PU
01/02Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
AQ
01/02EISAI : Receives the tokyo governor prize for corporate governance of the year® 2021
PU
31/01EISAI : Lenvima (Lenvatinib) in Combination with Keytruda (Pembrolizumab) Approved in Taiw..
AQ
31/01EISAI : Lenvima®(lenvatinib)in combination with keytruda®(pembrolizum..
PU
28/01Eisai announces results and continued support of initiatives for elimination of neglect..
AQ
28/01Biogen Inc. - Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
AQ
28/01Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglect..
AQ
28/01EISAI : Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
AQ
28/01EISAI : ANNOUNCES RESULTS AND CONTINUED SUPPORT OF INITIATIVES FOR ELIMINATION OF NEGLECTE..
PU
21/01Eisai - Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib..
AQ
20/01EISAI : Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) P..
AQ
1  2  3  4  5  6  7  8Volgende
Volgende evenement op EISAI CO., LTD.